News & Media Catch up with our latest releases here. Filter Article 44 Podcast 3 Video 25 Rita Ray 05/04/2024 Rita Ray 05/04/2024 OCT Company Update with Doceo OCT Company Update with Doceo Read More Rita Ray 05/04/2024 Rita Ray 05/04/2024 OCT’s Elevator Pitch with Doceo Read More Rita Ray 04/04/2024 Rita Ray 04/04/2024 The importance of patents Read More Rita Ray 04/04/2024 Rita Ray 04/04/2024 Cornerstone investor Cantheon is kudos for OCT Read More Rita Ray 04/04/2024 Rita Ray 04/04/2024 OCT Secures £1.205m to Advance Phase I Clinical Trial for Programme Two Video interview Read More Article Rob Bennett 19/12/2023 Article Rob Bennett 19/12/2023 Our year in review Our year in review Read More Article Rob Bennett 05/12/2023 Article Rob Bennett 05/12/2023 Trigeminal Neuralgia Explained Read More Video Rob Bennett 01/12/2023 Video Rob Bennett 01/12/2023 Oxford Cannabinoid Technologies Appoint Dr Tim Corn, CMO as Exec. Director Read More Article, Video Rob Bennett 20/11/2023 Article, Video Rob Bennett 20/11/2023 Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn Read More Article Rob Bennett 14/11/2023 Article Rob Bennett 14/11/2023 Directorate Appointment Read More Article Rob Bennett 01/11/2023 Article Rob Bennett 01/11/2023 How our regulatory approach differs from medical cannabis Read More Article, Video Rob Bennett 31/10/2023 Article, Video Rob Bennett 31/10/2023 Oxford Cannabinoid Technologies – executive interview Read More Article Rob Bennett 24/10/2023 Article Rob Bennett 24/10/2023 Oxford Cannabinoid Technologies PLC Read More Article Rob Bennett 24/10/2023 Article Rob Bennett 24/10/2023 OCT onboards new shareholders after Phase I results Read More Article Rob Bennett 16/10/2023 Article Rob Bennett 16/10/2023 Phase I Clinical Trials Results Read More Article Rob Bennett 10/10/2023 Article Rob Bennett 10/10/2023 Phase Clinical Trial Results Read More Article, Video Rob Bennett 10/10/2023 Article, Video Rob Bennett 10/10/2023 Oxford Cannabinoid Technologies CEO says objective "absolutely met" in lead asset trial Read More Article Rob Bennett 09/10/2023 Article Rob Bennett 09/10/2023 OCT launches new website Read More Article Rob Bennett 28/09/2023 Article Rob Bennett 28/09/2023 CIPN explained Read More Article Rob Bennett 27/09/2023 Article Rob Bennett 27/09/2023 OCT Emerges Strong from a Pivotal Year, Nears Release of Milestone Clinical Trial Results Read More Older Posts
Rita Ray 05/04/2024 Rita Ray 05/04/2024 OCT Company Update with Doceo OCT Company Update with Doceo Read More
Rita Ray 04/04/2024 Rita Ray 04/04/2024 OCT Secures £1.205m to Advance Phase I Clinical Trial for Programme Two Video interview Read More
Article Rob Bennett 19/12/2023 Article Rob Bennett 19/12/2023 Our year in review Our year in review Read More
Article Rob Bennett 05/12/2023 Article Rob Bennett 05/12/2023 Trigeminal Neuralgia Explained Read More
Video Rob Bennett 01/12/2023 Video Rob Bennett 01/12/2023 Oxford Cannabinoid Technologies Appoint Dr Tim Corn, CMO as Exec. Director Read More
Article, Video Rob Bennett 20/11/2023 Article, Video Rob Bennett 20/11/2023 Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn Read More
Article Rob Bennett 01/11/2023 Article Rob Bennett 01/11/2023 How our regulatory approach differs from medical cannabis Read More
Article, Video Rob Bennett 31/10/2023 Article, Video Rob Bennett 31/10/2023 Oxford Cannabinoid Technologies – executive interview Read More
Article Rob Bennett 24/10/2023 Article Rob Bennett 24/10/2023 Oxford Cannabinoid Technologies PLC Read More
Article Rob Bennett 24/10/2023 Article Rob Bennett 24/10/2023 OCT onboards new shareholders after Phase I results Read More
Article Rob Bennett 16/10/2023 Article Rob Bennett 16/10/2023 Phase I Clinical Trials Results Read More
Article, Video Rob Bennett 10/10/2023 Article, Video Rob Bennett 10/10/2023 Oxford Cannabinoid Technologies CEO says objective "absolutely met" in lead asset trial Read More
Article Rob Bennett 27/09/2023 Article Rob Bennett 27/09/2023 OCT Emerges Strong from a Pivotal Year, Nears Release of Milestone Clinical Trial Results Read More
